InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $2.000 -0.88 (-30.56%)+
Announcement
Release
14 Jan 2026 9:04AM
Price at Release
$2.880
Full Release
download
Summary
Racura Oncology Ltd has announced a significant collaboration with Emory University to investigate the use of (E,E)-bisantrene in combatting resistance in osimertinib-treated EGFR-mutated non-small cell lung cancer (NSCLC). This collaboration, led by Professor Shi-Yong Sun, focuses on leveraging Emory's expertise and unique osimertinib-resistant models to support Racura's HARNESS-1 clinical trial. The initiative aims to address emerging resistance to osimertinib and enhance patient survival by targeting resistant sub-clones. This partnership is strategic in strengthening scientific foundations and facilitating discussions with pharmaceutical partners for Racura’s RC220 (E,E-bisantrene).
Key Points
  • Racura Oncology Ltd has commenced a collaboration with Emory University to study (E,E)-bisantrene in osimertinib-resistant EGFR-mutated NSCLC.
  • The collaboration is led by Professor Shi-Yong Sun, a world-leader in osimertinib-resistant lung cancer biology.
  • Racura has access to Emory’s unique osimertinib-resistant cell and mouse NSCLC models and expertise.
  • The program supports the HARNESS-1 clinical trial of (E,E)-bisantrene aimed at delaying or preventing resistance to osimertinib.
  • The collaboration seeks to characterise the biology and mechanisms of resistance in EGFRm NSCLC.
  • Racura Oncology is aiming to extend progression-free and overall survival in patients by targeting osimertinib-resistant sub-clones.
  • Professor Sun’s expertise is pivotal in understanding the biology of impressive efficacy when combining (E,E)-bisantrene with osimertinib.
  • The collaboration is expected to produce high-quality, mechanism-informed preclinical data supporting RC220.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.